To address these knowledge gaps, we conducted a comprehensive systematic review and meta-analysis of the available literature to assess the clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis. The gene discussed is IL23A; the disease is psoriatic arthritis.